- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
InhaleRx Pens AU$38.5 Million Funding Agreement with Clendon Biotech Capital
The company will dedicate the funds to advancing Phase 1 and 2 clinical development of its key projects.
Australian healthcare company InhaleRx (ASX:IRX) has entered into a AU$38.5 million funding facility with Melbourne-based Clendon Biotech Capital to cover clinical trial costs for its key projects.
InhaleRx currently has two main projects: its pain asset IRX-211 and its mental health asset IRX-616a.
According to the company, IRX-211 is designed to target breakthrough cancer pain, while IRX-616a focuses on offering fast and effective relief for individuals suffering from panic disorder.
“This partnership ensures that InhaleRx can move forward with the next stages ... including the associated non-clinical work and trial drug manufacturing costs for the IRX-211 and IRX-616a drug development plans through to the completion of Phase 2 clinical trials,” the company said in a press release on October 18.
InhaleRx will use the AU$38.5 million from Clendon to sustain both of its projects until they reach the pivotal Phase 3 stage within the next two to three years. During this time, the company will remain responsible for covering operational and corporate overhead costs that are not included in the scope of its agreement with Clendon.
Repayment terms are tied to project completion, and the funding facility has an interest rate of 15 percent per year.
“(InhaleRx) must repay the money owed in cash, but may use the proceeds from the exercise of the options to make the repayments,” InhaleRx says in its release. Clendon will also receive options in InhaleRx as part of the deal.
InhaleRx received the final clinical study report for a Phase 1 trial of IRX-211 in July. The company was encouraged by the results and is set to commence a Phase 2 trial for the drug toward the end of this year.
Also in July, the US Food and Drug Administration temporarily suspended InhaleRx's investigational new drug application for a Phase 1 trial involving IRX-616a. The company said it is working address the concerns identified.
Investigational new drug status isn't required for Phase 1 and 2 clinical trials in Australia.
Don’t forget to follow us @INN_Australia for real-time news updates!
Securities Disclosure: I, Gabrielle de la Cruz, hold no direct investment interest in any company mentioned in this article.
2024 Life Science Outlook Report
Get the trends and expert predictions you need to stay ahead of the markets.
Download your outlook report today.
Learn About Exciting Investing Opportunities in the Life Science Sector
Your Newsletter Preferences
Gabbie graduated with a journalism degree from Colegio de San Juan de Letran - Manila and has produced articles on a variety of topics, such as infrastructure, business and technology. Her creative portfolio includes written work on architecture, art and design. Gabbie covers the Australian market for the Investing News Network, focusing on the mining sector.
When not in front of her desk, she is out scanning through vinyl records, exploring the international coffee culture and fighting for queer rights.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Gabbie graduated with a journalism degree from Colegio de San Juan de Letran - Manila and has produced articles on a variety of topics, such as infrastructure, business and technology. Her creative portfolio includes written work on architecture, art and design. Gabbie covers the Australian market for the Investing News Network, focusing on the mining sector.
When not in front of her desk, she is out scanning through vinyl records, exploring the international coffee culture and fighting for queer rights.
Learn about our editorial policies.